GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution

Annals of Hematology

Volumn 94, Issue 2, 2015, Pages 211-221

  Hou, Hsin An ^a   Lin, Yun Chu ^a   Kuo, Yuan Yeh ^b   Chou, Wen Chien ^a   Lin, Chien Chin ^a   Liu, Chieh Yu ^c   Chen, Chien Yuan ^a   Lin, Liang In ^b   Tseng, Mei Hsuan ^a   Huang, Chi Fei ^a   Chiang, Ying Chieh ^a   Liu, Ming Chih ^a   Liu, Chia Wen ^a   Tang, Jih Luh ^a   Yao, Ming ^a   Huang, Shang Yi ^a   Ko, Bor Sheng ^a   Hsu, Szu Chun ^a   Wu, Shang Ju ^a   Tsay, Woei ^a   Chen, Yao Chang ^a   Tien, Hwei Fang ^a   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

Author keywords

AML; Disease progression; GATA2 mutations; Genetic alterations; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD15 ANTIGEN; CD34 ANTIGEN; CD7 ANTIGEN; HLA DR ANTIGEN; TRANSCRIPTION FACTOR GATA 2; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; GATA2 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; AMINO TERMINAL SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; EXON; FEMALE; FOLLOW UP; GATA2 GENE; GENE; GENETIC RISK; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; KARYOTYPE; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; SEQUENTIAL ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE; YOUNG ADULT; ZINC FINGER MOTIF; ACUTE DISEASE; ADOLESCENT; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MUTATION; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CCAAT-ENHANCER-BINDING PROTEINS; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GATA2 TRANSCRIPTION FACTOR; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; KARYOTYPE; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; YOUNG ADULT;

EID: 84926678734     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2208-8     Document Type: Article

References (30)

1. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M, Alt FW, Orkin SH (1994) An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371(6494):221–226. doi:10.1038/371221a0
2. Tsai FY, Orkin SH (1997) Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood 89(10):3636–3643
3. Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, Babic M, Lin M, Carmagnac A, Lee YK, Kok CH, Gagliardi L, Friend KL, Ekert PG, Butcher CM, Brown AL, Lewis ID, To LB, Timms AE, Storek J, Moore S, Altree M, Escher R, Bardy PG, Suthers GK, D’Andrea RJ, Horwitz MS, Scott HS (2011) Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 43(10):1012–1017. doi:10.1038/ng.913
4. Zhang SJ, Ma LY, Huang QH, Li G, Gu BW, Gao XD, Shi JY, Wang YY, Gao L, Cai X, Ren RB, Zhu J, Chen Z, Chen SJ (2008) Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A 105(6):2076–2081. doi:10.1073/pnas.0711824105
5. Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthaus T, Herold T, Yaghmaie M, Dorge P, Hopfner KP, Hauser A, Graf A, Krebs S, Blum H, Kakadia PM, Schneider S, Hoster E, Schneider F, Stanulla M, Braess J, Sauerland MC, Berdel WE, Buchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK (2012) GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 120(2):395–403. doi:10.1182/blood-2012-01-403220
6. Fasan A, Eder C, Haferlach C, Grossmann V, Kohlmann A, Dicker F, Kern W, Haferlach T, Schnittger S (2013) GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia 27(2):482–485. doi:10.1038/leu.2012.174
7. Green CL, Tawana K, Hills RK, Bodor C, Fitzgibbon J, Inglott S, Ancliff P, Burnett AK, Linch DC, Gale RE (2013) GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. Br J Haematol 161(5):701–705. doi:10.1111/bjh.12317
8. Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, Liang WX, Mi JQ, Song HD, Li KQ, Chen Z, Chen SJ (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43(4):309–315. doi:10.1038/ng.788
9. Shiba N, Funato M, Ohki K, Park MJ, Mizushima Y, Adachi S, Kobayashi M, Kinoshita A, Sotomatsu M, Arakawa H, Tawa A, Horibe K, Tsukimoto I, Hayashi Y (2013) Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia. Br J Haematol. doi:10.1111/bjh.12559
10. Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY, Lin LI, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF (2012) DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 119(2):559–568. doi:10.1182/blood-2011-07-369934
11. Hou HA, Lin CC, Chou WC, Liu CY, Chen CY, Tang JL, Lai YJ, Tseng MH, Huang CF, Chiang YC, Lee FY, Kuo YY, Lee MC, Liu MC, Liu CW, Lin LI, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF (2014) Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 28(1):50–58. doi:10.1038/leu.2013.236
12. Tien HF, Wang CH, Lin MT, Lee FY, Liu MC, Chuang SM, Chen YC, Shen MC, Lin KH, Lin DT (1995) Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 84(1):60–68
13. Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, Huang CF, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Lin LI, Tien HF (2009) AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 114(26):5352–5361. doi:10.1182/blood-2009-05-223784
14. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY, Wu SJ, Huang CF, Chiou RJ, Tseng MH, Lin DT, Lin KH, Chen YC, Tien HF (2006) Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 66(6):3310–3316
15. Chen CY, Lin LI, Tang JL, Tsay W, Chang HH, Yeh YC, Huang CF, Chiou RJ, Yao M, Ko BS, Chen YC, Lin KH, Lin DT, Tien HF (2006) Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 20(6):1155–1158
16. Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC, Yao M, Wu SJ, Tseng MH, Tien HF (2007) RUNX1 gene mutation in primary myelodysplastic syndrome–the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 139(3):405–414. doi:10.1111/j.1365-2141.2007.06811.x
17. Hou HA, Chou WC, Lin LI, Chen CY, Tang JL, Tseng MH, Huang CF, Chiou RJ, Lee FY, Liu MC, Tien HF (2008) Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. Leukemia 22(5):1075–1078. doi:10.1038/sj.leu.2405005
18. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, Shen HL, Su FH, Yao M, Huang SY, Tien HF (2005) Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 11(4):1372–1379
19. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254–266
20. Hou HA, Huang TC, Lin LI, Liu CY, Chen CY, Chou WC, Tang JL, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF (2010) WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 115(25):5222–5231. doi:10.1182/blood-2009-12-259390
21. Shiah HS, Kuo YY, Tang JL, Huang SY, Yao M, Tsay W, Chen YC, Wang CH, Shen MC, Lin DT, Lin KH, Tien HF (2002) Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia 16(2):196–202
22. Chen TC, Hou HA, Chou WC, Tang JL, Kuo YY, Chen CY, Tseng MH, Huang CF, Lai YJ, Chiang YC, Lee FY, Liu MC, Liu CW, Liu CY, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF (2014) Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J 4:e177. doi:10.1038/bcj.2013.74
23. Lin CC, Hou HA, Chou WC, Kuo YY, Liu CY, Chen CY, Lai YJ, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Liu CW, Tang JL, Yao M, Huang SY, Ko BS, Wu SJ, Tsay W, Chen YC, Tien HF (2013) IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol. doi:10.1002/ajh.23596
24. Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF (2011) The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25(2):246–253. doi:10.1038/leu.2010.267
25. Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF (2011) TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. doi:10.1182/blood-2011-02-339747
26. Hou HA, Kuo YY, Tang JL, Chou WC, Yao M, Lai YJ, Lin CC, Chen CY, Liu CY, Tseng MH, Huang CF, Chiang YC, Lee FY, Liu MC, Liu CW, Huang SY, Ko BS, Wu SJ, Tsay W, Chen YC, Tien HF (2013) Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Am J Hematol. doi:10.1002/ajh.23611
27. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642–4649. doi:10.1200/JCO.2003.04.036
28. Meshinchi S, Arceci RJ (2007) Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 12(3):341–355. doi:10.1634/theoncologist.12-3-341
29. von Neuhoff C, Reinhardt D, Sander A, Zimmermann M, Bradtke J, Betts DR, Zemanova Z, Stary J, Bourquin JP, Haas OA, Dworzak MN, Creutzig U (2010) Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 28(16):2682–2689. doi:10.1200/JCO.2009.25.6321
30. Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF (2010) Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 116(20):4086–4094. doi:10.1182/blood-2010-05-283291